Small physician practices now have a new way to access the COVID-19 preexposure drug Evusheld, and in smaller amounts.
Practices also can benefit from a new helpline for information on the monoclonal antibody treatment that helps prevent COVID-19 infection among immunocompromised patients at high risk of severe illness.
The U.S. Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR) set up the new pathway in partnership with AstraZeneca for “individual providers and smaller sites of care that do not currently receive Evusheld through the HHS Health Partner Order Portal (or HPOP) distribution process,” HHS said. Those entities can use the pathway to order “small, limited quantities of the drug” directly from the manufacturer in amounts of one to three patient courses.
Evusheld is one of several COVID-19 therapeutics ASPR allocates and provides at no cost.
In addition, AstraZeneca created a helpline – 1-833-EVUSHLD (1-833-388-7453) – physicians may call to get general information about the treatment and specific guidance on how to access and order it.
Find the order form, hotline, and other information on this HHS website.
Also, be sure to check out the Food and Drug Administration’s revised dosing recommendations for Evusheld, which is authorized for people aged 12 and older and given as two consecutive intramuscular injections.
Last Updated On
August 05, 2022
Originally Published On
August 05, 2022
Amy Lynn Sorrel
Associate Vice President, Editorial Strategy & Programming
Division of Communications and Marketing
(512) 370-1384